HealthX Q4 FY26 Earnings Call Transcript Released; Focus on Growth and Restructuring
HealthX Platform Limited released its Q4 FY26 earnings call transcript. Revenue for Q4 FY26 grew 22% YoY to ₹356 crore, and full-year FY26 revenue reached ₹1283 crore, up 18% YoY. The company plans a corporate restructuring, demerging its finance division into Microsec Resources Ltd. HealthX targets ₹6,000 crore revenue by FY30.
The announcement includes significant financial performance updates, a major corporate restructuring involving demerger and separate listing, and clear long-term revenue targets, all of which are material to investors.
The company reported strong year-on-year revenue growth, improved EBITDA margins, and a significant reduction in PAT loss. The strategic restructuring and clear future growth targets also contribute to a positive outlook.
Health X Platform Limited (formerly SastaSundar Ventures Limited) has released the transcript of its Group Conference Call held on June 12, 2026, to discuss performance for Q4 and FY26, ending March 31, 2026. The company highlighted its transition to the HealthX identity, signifying an evolution into a broader healthcare ecosystem.
Key financial and operational updates were provided. For Q4 FY26, revenue from operations increased by 22% year-on-year to ₹356 crore, with gross profit rising 45% to ₹26.5 crore and gross margins improving to 7.3%. EBITDA losses reduced by 29% to ₹20 crore, with EBITDA margins improving to -5.5%. The PAT loss for the quarter was ₹12.9 crore, compared to a profit of ₹17.6 crore in Q4 FY25, mainly due to lower other income and exceptional items.
For the full year FY26, revenue from operations was ₹1283 crore, an 18% year-on-year growth. Gross profit increased by 36.5% to ₹96.5 crore, with gross margins improving to 7.5%. EBITDA losses reduced to ₹65 crore from ₹79 crore in FY25, with EBITDA margins improving to -5%. The PAT loss for FY26 was ₹1.4 crore, a significant improvement from a loss of ₹133 crore in FY25.
The company reiterated its focus on accelerating Retailer Shakti's growth, scaling the consumer healthcare platform, and expanding the JITO ecosystem. HealthX targets ₹6,000 crore in revenue by FY30, with ₹4,000 crore from Retailer Shakti (B2B) and ₹2,000 crore from SastaSundar (B2C).
A significant corporate action announced is the approved scheme of simplification of the corporate structure. The Finance Division will be demerged and listed separately as Microsec Resources Ltd. Existing HealthX shareholders will receive one equity share of Microsec Resources for every three shares held in HealthX Platform. The healthcare business, including treasury of approximately ₹400 crore, will remain with HealthX Platform, while Microsec Resources will have an asset base of approximately ₹140 crore, including financial assets and real estate.
Future plans include expanding product offerings to personal care and beauty care by December 2026, with non-medicine revenue targeted to reach 10% of sales within a year. The company is also investing in technology and automation, with a total capex of ₹234 crore planned for new warehouses, funded by bank loans and treasury. HealthX aims for a peak EBITDA margin of around 5% and PAT of 4% at ₹6,000 crore revenue scale. ROE is projected to be significantly higher by FY29-FY30, targeting around 40%.
What to do with a filing like this
Health X Platform Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Health X Platform Limited. Read the original for the full detail.